WHAT IS CLAIMED IS:

1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof:



(I),

wherein

R^1 is -H, -C_{1-6} alkyl, -C_{3-6} cycloalkyl, or -C_{1-6} alkyl which is substituted with 1 or 2 substituents each of which is independently:

(1) C_{3-8} cycloalkyl,

(2) aryl,

(3) a 5- or 6-membered saturated or mono-unsaturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S,

(4) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, or

(5) a 9- or 10-membered fused bicyclic heterocycle containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein at least one of the rings is aromatic;

wherein

(A) each cycloalkyl is optionally substituted with from 1 to 3 substituents, each of which is independently halo, -C_{1-6} alkyl, or -O-C_{1-6} alkyl;

(B) each aryl is optionally substituted with from 1 to 5 substituents each of which is independently

(1) -C_{1-6} alkyl, optionally substituted with from 1 to 3 substituents each of which is independently -OH, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, -CN, -NO_2, -$N(R^aR^b)$, -$C(=O)N(R^aR^b)$, -$C(=O)R^a$, -CO_2R^c, -$S(O)_nR^c$, -$SO_2N(R^aR^b)$, -$N(R^a)C(=O)R^b$, -$N(R^a)CO_2R^c$, -$N(R^a)SO_2R^c$, -$N(R^a)SO_2N(R^aR^b)$, -$OC(=O)N(R^aR^b)$, or -$N(R^a)C(=O)N(R^aR^b)$,

(2) -O-C_{1-6} alkyl, optionally substituted with from 1 to 3 substituents each of which is independently -OH, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, -$S(O)_n R^c$, -$C(=O)N(R^aR^b)$, -$SO_2N(R^aR^b)$, -$N(R^a)C(=O)R^b$, -$N(R^a)CO_2R^c$, -$N(R^a)SO_2R^c$, -$N(R^a)SO_2N(R^aR^b)$, -$OC(=O)N(R^aR^b)$, or -$N(R^a)C(=O)N(R^aR^b)$,

(3) -C_{1-6} haloalkyl,

(4) -O-C_{1-6} haloalkyl,

(5) -OH,

(6) halo,

(7) -CN,

(8) -NO_2,

(9) -$N(R^aR^b)$,

(10) -$C(=O)N(R^aR^b)$,

(11) -$C(=O)R^a$,

(12) -CO_2R^c,

(13) -SR^c,

(14) -$S(=O)R^c$,

(15) -SO_2R^c,

(16) -$N(R^a)SO_2R^c$,

(17) -$SO_2N(R^aR^b)$,

(18) -$N(R^a)C(=O)R^b$, or

(19) -$N(R^a)CO_2R^c$;

(C) each saturated or mono-unsaturated heterocyclic ring is

(i) optionally substituted with from 1 to 5 substituents each of which is independently halogen, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, or oxo; and

(ii) optionally substituted with 1 or 2 substituents each of which is independently aryl or a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; and

(D) each heteroaromatic ring or each fused bicyclic heterocycle is

(i) optionally substituted with from 1 to 7 substituents each of which is independently halogen, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, or oxo; and

(ii) optionally substituted with 1 or 2 substituents each of which is independently aryl or -C_{1-6} alkyl-aryl;

R^2 is -H or -C_{1-6} alkyl;

R^3 is -H, -C_{1-6} alkyl, -C_{1-6} haloalkyl, or -C_{1-6} alkyl substituted with one of -OH, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, -CN, -NO_2, -$N(R^aR^b)$, -$C(=O)N(R^aR^b)$, -$C(=O)R^a$, -CO_2R^c, -$S(O)_nR^c$, -$SO_2N(R^aR^b)$, -$N(R^a)C(=O)R^b$, -$N(R^a)CO_2R^c$, -$N(R^a)SO_2R^c$, -$N(R^a)SO_2N(R^aR^b)$, -$OC(=O)N(R^aR^b)$, or -$N(R^a)C(=O)N(R^aR^b)$;

R^4 is:

(1) -H,

(2) -C_{1-6} alkyl optionally substituted with one of -OH, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, -CN, -NO_2, -$N(R^aR^b)$, -$C(=O)N(R^aR^b)$, -$C(=O)R^a$, -CO_2R^c, -$S(O)_nR^c$, -$SO_2N(R^aR^b)$, -$N(R^a)$-$C(R^b)$=O, -$N(R^a)SO_2R^c$, -$N(R^a)SO_2N(R^aR^b)$, -$OC(=O)N(R^aR^b)$, -$N(R^a)C(=O)N(R^aR^b)$, -O-C_{1-6} alkyl-$C(=O)N(R^aR^b)$, -S-C_{1-6} alkyl-$C(=O)N(R^aR^b)$, -$N(R^a)$-C_{1-6} alkyl-$C(=O)N(R^aR^b)$, or -$N(SO_2R^c)$-C_{1-6} alkyl-$C(=O)N(R^aR^b)$,

(3) -C_{1-6} haloalkyl,

(4) -$C(=O)R^a$,

(5) -CO_2R^c,

(6) -$C(=O)N(R^aR^b)$,

(7) -$SO_2N(R^aR^b)$,

(8) -C_{2-6} alkenyl,

(9) -C_{2-6} alkenyl-$C(=O)$-$N(R^a)_2$,

(10) -C_{2-5} alkynyl,

(11) -C_{2-5} alkynyl-$CH_2N(R^a)_2$,

(12) -C_{2-5} alkynyl-CH_2OR^a,

(13) -C_{2-5} alkynyl-$CH_2S(O)_nR^c$, or

(14) -R^k,

(15) -C_{1-6} alkyl substituted with R^k,

(16) -C_{1-6} haloalkyl substituted with R^k,
(17) -C_{1-6} alkyl-O-R^k,
(18) -C_{1-6} alkyl-O-C_{1-6} alkyl-R^k,
(19) -C_{1-6} alkyl-$S(O)_n$-R^k,
(20) -C_{1-6} alkyl-$S(O)_n$-C_{1-6} alkyl-R^k,
(21) -C_{1-6} alkyl-$N(R^a)$-R^k,
(22) -C_{1-6} alkyl-$N(R^a)$-C_{1-6} alkyl-R^k,
(23) -C_{1-6} alkyl-$N(R^a)$-C_{1-6} alkyl-OR^k, with the proviso that the -$N(R^a)$- moiety and the -OR^k moiety are not both attached to the same carbon of the -C_{1-6} alkyl- moiety,
(24) -C_{1-6} alkyl-C(=O)-R^k,
(25) -C_{1-6} alkyl-C(=O)$N(R^a)$-R^k,
(26) -C_{1-6} alkyl-$N(R^a)$C(=O)-R^k,
(27) -C_{1-6} alkyl-C(=O)$N(R^a)$-C_{1-6} alkyl-R^k, or
(28) -C_{1-6} alkyl-$N(R^a)$-C_{0-6} alkyl-$S(O)_nR^k$;

wherein R^k is

(i) aryl, which is optionally substituted with from 1 to 5 substituents each of which is independently -C_{1-6} alkyl, -C_{1-6} alkyl-OH, -C_{1-6} alkyl-O-C_{1-6} alkyl, -C_{1-6} alkyl-O-C_{1-6} haloalkyl, -C_{1-6} alkyl-$N(R^aR^b)$, -C_{1-6} alkyl-C(=O)$N(R^aR^b)$, -C_{1-6} alkyl-C(=O)R^a, -C_{1-6} alkyl-CO_2R^c, -C_{1-6} alkyl-$S(O)_nR^c$, -O-C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} haloalkyl, -OH, halo, -$N(R^aR^b)$, -C(=O)$N(R^aR^b)$, -C(=O)R^a, -CO_2R^c, -$S(O)_nR^c$, or -$SO_2N(R^aR^b)$;

(ii) a 4- to 7-membered saturated or mono-unsaturated heterocyclic ring containing at least one carbon atom and from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heterocyclic ring is:

(a) optionally substituted with from 1 to 5 substituents each of which is independently halogen, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, or oxo; and

(b) optionally mono-substituted with aryl or HetA;

wherein HetA is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally fused with a benzene ring, and HetA is optionally substituted with from 1 to 4

substituents each of which is independently -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, or oxo; or

(iii) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from optionally substituted with from 1 to 4 substituents each of which is independently -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, or oxo;

R^5 is -H or -C_{1-6} alkyl;

R^6 is:

(1) -OH,
(2) -O-C_{1-6} alkyl,
(3) -N(R^uR^v),
(4) -O-C_{1-6} haloalkyl,
(5) -O-C_{1-6} alkyl-aryl
(6) -O-C_{1-6} alkyl-HetB, or
(7) -O-C_{1-6} alkyl-HetC,

wherein

R^u is -H or -C_{1-6} alkyl;

R^v independently has the same definition as R^1;

HetB is a 5- or 6-membered saturated or mono-unsaturated ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the ring is optionally substituted with from 1 to 5 substituents each of which is independently halogen, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, or oxo; and

HetC is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, or oxo;

each R^a and R^b is independently -H or -C_{1-6} alkyl;

each R^c is independently a -C_{1-6} alkyl; and

each n is independently an integer equal to 0, 1 or 2.

2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:

R^1 is -C_{1-4} alkyl mono-substituted with aryl; wherein the aryl is optionally substituted with from 1 to 4 substituents each of which is independently

(1) -C_{1-4} alkyl, optionally mono-substituted with -OH, -O-C_{1-4} alkyl, -O-C_{1-4} haloalkyl, -CN, -$N(R^aR^b)$, -$C(=O)N(R^aR^b)$, -$C(=O)R^a$, -CO_2R^c, -$S(O)_nR^c$, -$SO_2N(R^aR^b)$, -$N(R^a)C(=O)R^b$, -$N(R^a)CO_2R^c$, -$N(R^a)SO_2R^c$, -$N(R^a)SO_2N(R^aR^b)$, -$OC(=O)N(R^aR^b)$, or -$N(R^a)C(=O)N(R^aR^b)$,

(2) -O-C_{1-4} alkyl, optionally mono-substituted with -OH, -O-C_{1-4} alkyl, -O-C_{1-4} haloalkyl, -$S(O)_nR^c$, -$N(R^a)$-CO_2R^c, -$C(=O)N(R^aR^b)$, -$SO_2N(R^aR^b)$, -$N(R^a)C(=O)R^b$, -$N(R^a)CO_2R^c$, -$N(R^a)SO_2R^c$, -$N(R^a)SO_2N(R^aR^b)$, -$OC(=O)N(R^aR^b)$, or -$N(R^a)C(=O)N(R^aR^b)$,

(3) -C_{1-4} haloalkyl,

(4) -O-C_{1-4} haloalkyl,

(5) -OH,

(6) halo,

(7) -CN,

(8) -NO_2,

(9) -$N(R^aR^b)$,

(10) -SR^c,

(11) -$S(=O)R^c$,

(12) -SO_2R^c,

(13) -$N(R^a)SO_2R^c$,

(14) -$SO_2N(R^aR^b)$,

(15) -$N(R^a)C(=O)R^b$, or

(16) -$N(R^a)CO_2R^c$; and

R^6 is:

(1) -OH,

(2) -O-C_{1-6} alkyl,
(3) -N(R^uR^v),
(4) -O-C_{1-6} haloalkyl,
(5) -O-C_{1-6} alkyl-aryl
(6) -O-C_{1-6} alkyl-HetB, or
(7) -O-C_{1-6} alkyl-HetC,

wherein

R^u is -H or -C_{1-6} alkyl;

R^v is -H, -C_{1-6} alkyl, -C_{3-6} cycloalkyl, or independently has the same definition as R^1 above;

HetB is a 5- or 6-membered saturated or mono-unsaturated ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the ring is optionally substituted with from 1 to 5 substituents each of which is independently halogen, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, or oxo; and

HetC is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, or oxo.

3. The compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein in R^1 is -$(CH_2)_{1-4}$-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently

(1) -C_{1-4} alkyl, optionally mono-substituted with -OH, -O-C_{1-4} alkyl, -O-C_{1-4} haloalkyl, -CN, -N(R^aR^b), -C(=O)N(R^aR^b), -C(=O)R^a, -CO_2R^c, -$S(O)_nR^c$, or -SO_2N(R^aR^b),
(2) -O-C_{1-4} alkyl,
(3) -C_{1-4} haloalkyl,
(4) -O-C_{1-4} haloalkyl,
(5) -OH,
(6) halo,
(7) -CN,
(8) -NO_2,

(9) -N(R^aR^b),
(10) -SR^c,
(11) -S(=O)R^c,
(12) -SO_2R^c,
(13) -N(R^a)SO_2R^c,
(14) -SO_2N(R^aR^b),
(15) -N(R^a)C(=O)R^b, or
(16) -N(R^a)CO_2R^c.

4. The compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein R^1 is:



;

wherein X^1 and X^2 are each independently
(1) -H,
(2) methyl,
(3) ethyl,
(4) methoxy,
(5) ethoxy,
(6) -CF_3,
(7) fluoro,
(8) bromo, or
(9) chloro.

5. The compound according to claim 4, or a pharmaceutically acceptable salt thereof, wherein R^1 is 4-fluorobenzyl.

6. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:

R^2 is -H or -C_{1-4} alkyl;

R^3 is -H or -C_{1-4} alkyl;

R^4 is:

(1) -H,
(2) -C_{1-4} alkyl optionally substituted with one of -OH, -O-C_{1-4} alkyl, -O-C_{1-4} haloalkyl, -CN, -N(R^aR^b), -C(=O)N(R^aR^b), -C(=O)R^a, -CO_2R^c, -S(O)$_n$$R^c$, -$SO_2$N($R^aR^b$), -N($R^a$)-C($R^b$)=O, -N($R^a$)$SO_2R^b$, or -N($R^a$)$SO_2$N($R^aR^b$),
(3) -C(=O)N(R^aR^b),
(4) -R^k,
(5) -C_{1-4} alkyl substituted with R^k,
(6) -C_{1-4} alkyl-O-R^k, or
(7) -C_{1-4} alkyl-O-C_{1-4} alkyl-R^k; and

R^5 is -H.

7. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R^6 is:

(1) -OH,
(2) -O-C_{1-4} alkyl,
(3) -N(R^uR^v),
(4) -O-C_{1-4} haloalkyl,
(5) -O-C_{1-4} alkyl-aryl
(6) -O-C_{1-4} alkyl-HetB, or
(7) -O-C_{1-4} alkyl-HetC,

wherein

R^u is -H or -C_{1-4} alkyl;

R^v is -H, -C_{1-4} alkyl, or cyclopropyl;

HetB is a 5- or 6-membered saturated ring containing a total of from 1 to 4 heteroatoms independently selected from 1 to 4 N atoms, from 0 to 2 O atoms, and from 0 to 2 S atoms, wherein the saturated ring is optionally substituted with from 1 to 4 substituents each of which is independently halogen, -C_{1-4} alkyl, -C_{1-4} haloalkyl, -O-C_{1-4} alkyl, -O-C_{1-4} haloalkyl, or oxo; and

HetC is a 5- or 6-membered heteroaromatic ring containing a total of from 1 to 4 heteroatoms independently selected from 1 to 4 N atoms, from 0 to 2 O atoms, and from 0 to 2 S atoms, wherein the heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently -C_{1-4} alkyl, -C_{1-4} haloalkyl, -O-C_{1-4} alkyl, -O-C_{1-4} haloalkyl, or oxo.

8. A compound of Formula (II), or a pharmaceutically acceptable salt thereof:



(II),

wherein:

$X^{1'}$ and $X^{2'}$ are each independently:

(1) -H,
(2) C_{1-4} alkyl,
(2) -O-C_{1-4} alkyl,
(3) -C_{1-4} haloalkyl,
(4) -O-C_{1-4} haloalkyl, or
(5) halo; and

$R^{6'}$ is:

(1) -OH,
(2) -O-C_{1-4} alkyl, or
(3) -$N(R^uR^v)$;

wherein

R^u is -H or -C_{1-4} alkyl; and

R^v is -C_{1-4} alkyl or cyclopropyl.

9. A compound according to claim 8, or a pharmaceutically acceptable salt thereof, wherein:

wherein $X^{1'}$ and $X^{2'}$ are each independently:

(1) -H,
(2) methyl,
(2) $-OCH_3$,
(3) $-CF_3$,
(4) $-OCF_3$,
(5) chloro,
(6) fluoro, or
(7) bromo; and

$R^{6'}$ is:

(1) -OH,
(2) methoxy
(3) ethoxy
(4) $-N(R^uR^v)$;

wherein

R^u is -H; and

R^v is methyl, ethyl, or cyclopropyl.

10. The compound according to claim 8, which is a compound of Formula (III), or a pharmaceutically acceptable salt thereof:



(III),

wherein $X^{1'}$ and $X^{2'}$ are each independently -H or halo.

11. The compound according to claim 10, or a pharmaceutically acceptable salt thereof, wherein

$X^{1'}$ and $X^{2'}$ are each independently -H, fluoro, chloro, or bromo; and

$R^{6'}$ is:

(1) -OH,
(2) methoxy
(3) ethoxy
(4) -N(R^uR^v);
wherein
R^u is -H; and
R^v is methyl, ethyl, or cyclopropyl.

12. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, which is a compound of Formula (IV):



(IV),

wherein

R^u is -H or -C_{1-6} alkyl;

R^v is C_{1-6} alkyl which is substituted with 1 or 2 substituents each of which is independently:
(1) C_{3-8} cycloalkyl,
(2) aryl,
(3) a 5- or 6-membered saturated or mono-unsaturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S,
(4) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, or
(5) a 9- or 10-membered fused bicyclic heterocycle containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein at least one of the rings is aromatic;
wherein
(A) each cycloalkyl is optionally substituted with from 1 to 3 substituents, each of which is independently halo, -C_{1-6} alkyl, or -O-C_{1-6} alkyl;

(B) each aryl is optionally substituted with from 1 to 5 substituents each of which is independently

(1) -C_{1-6} alkyl, optionally substituted with from 1 to 3 substituents each of which is independently -OH, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, -CN, -NO_2, -$N(R^aR^b)$, -$C(=O)N(R^aR^b)$, -$C(=O)R^a$, -CO_2R^c, -$S(O)_nR^c$, -$SO_2N(R^aR^b)$, -$N(R^a)C(=O)R^b$, -$N(R^a)CO_2R^c$, -$N(R^a)SO_2R^c$, -$N(R^a)SO_2N(R^aR^b)$, -$OC(=O)N(R^aR^b)$, or -$N(R^a)C(=O)N(R^aR^b)$,

(2) -O-C_{1-6} alkyl, optionally substituted with from 1 to 3 substituents each of which is independently -OH, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, -$S(O)_nR^c$, -$C(=O)N(R^aR^b)$, -$SO_2N(R^aR^b)$, -$N(R^a)C(=O)R^b$, -$N(R^a)CO_2R^c$, -$N(R^a)SO_2R^c$, -$N(R^a)SO_2N(R^aR^b)$, -$OC(=O)N(R^aR^b)$, or -$N(R^a)C(=O)N(R^aR^b)$,

(3) -C_{1-6} haloalkyl,

(4) -O-C_{1-6} haloalkyl,

(5) -OH,

(6) halo,

(7) -CN,

(8) -NO_2,

(9) -$N(R^aR^b)$,

(10) -$C(=O)N(R^aR^b)$,

(11) -$C(=O)R^a$,

(12) -CO_2R^c,

(13) -SR^c,

(14) -$S(=O)R^c$,

(15) -SO_2R^c,

(16) -$N(R^a)SO_2R^c$,

(17) -$SO_2N(R^aR^b)$,

(18) -$N(R^a)C(=O)R^b$, or

(19) -$N(R^a)CO_2R^c$;

(C) each saturated or mono-unsaturated heterocyclic ring is

(i) optionally substituted with from 1 to 5 substituents each of which is independently halogen, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, or oxo; and

(ii) optionally substituted with 1 or 2 substituents each of which is independently aryl or a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; and

(D) each heteroaromatic ring or each fused bicyclic heterocycle is

(i) optionally substituted with from 1 to 7 substituents each of which is independently halogen, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, or oxo; and

(ii) optionally substituted with 1 or 2 substituents each of which is independently aryl or -C_{1-6} alkyl-aryl; and

R^1 is -H or -C_{1-6} alkyl.

13. The compound according to claim 12, or a pharmaceutically acceptable salt thereof, wherein R^V is -C_{1-4} alkyl mono-substituted with aryl; wherein the aryl is optionally substituted with from 1 to 4 substituents each of which is independently

(1) -C_{1-4} alkyl, optionally mono-substituted with -OH, -O-C_{1-4} alkyl, -O-C_{1-4} haloalkyl, -CN, -$N(R^aR^b)$, -$C(=O)N(R^aR^b)$, -$C(=O)R^a$, -CO_2R^c, -$S(O)_nR^c$, -$SO_2N(R^aR^b)$, -$N(R^a)C(=O)R^b$, -$N(R^a)CO_2R^c$, -$N(R^a)SO_2R^c$, -$N(R^a)SO_2N(R^aR^b)$, -$OC(=O)N(R^aR^b)$, or -$N(R^a)C(=O)N(R^aR^b)$,

(2) -O-C_{1-4} alkyl, optionally mono-substituted with -OH, -O-C_{1-4} alkyl, -O-C_{1-4} haloalkyl, -$S(O)_nR^c$, -$N(R^a)$-CO_2R^c, -$C(=O)N(R^aR^b)$, -$SO_2N(R^aR^b)$, -$N(R^a)C(=O)R^b$, -$N(R^a)CO_2R^c$, -$N(R^a)SO_2R^c$, -$N(R^a)SO_2N(R^aR^b)$, -$OC(=O)N(R^aR^b)$, or -$N(R^a)C(=O)N(R^aR^b)$,

(3) -C_{1-4} haloalkyl,

(4) -O-C_{1-4} haloalkyl,

(5) -OH,

(6) halo,

(7) -CN,

(8) -NO_2,

(9) -$N(R^aR^b)$,

(10) -SR^c,
(11) -$S(=O)R^c$,
(12) -SO_2R^c,
(13) -$N(R^a)SO_2R^c$,
(14) -$SO_2N(R^aR^b)$,
(15) -$N(R^a)C(=O)R^b$, or
(16) -$N(R^a)CO_2R^c$.

14. The compound according to claim 13, or a pharmaceutically acceptable salt thereof, wherein R^v is:



;

wherein X^1 and X^2 are each independently
(1) -H,
(2) methyl,
(3) ethyl,
(4) methoxy,
(5) ethoxy,
(6) -CF_3,
(7) fluoro,
(8) bromo, or
(9) chloro.

15. The compound according to claim 14, or a pharmaceutically acceptable salt thereof, wherein R^v is 4-fluorobenzyl.

16. The compound according to claim 12, or a pharmaceutically acceptable salt thereof, wherein:

R^u is -H;

R^5 is -H;

R^4 is:

(1) -H,

(2) -C_{1-4} alkyl optionally substituted with one of -OH, -$N(R^aR^b)$, or -$C(=O)N(R^aR^b)$,

(3) -$C(=O)N(R^aR^b)$,

(4) -$(CH_2)_{1-3}$-R^k,

(5) -$(CH_2)_{1-3}$-O-R^k, or

(6) -$(CH_2)_{1-3}$-O-$(CH_2)_{1-3}$-R^k;

R^2 is -H; and

R^1 is -C_{1-4} alkyl.

17. A compound selected from the group consisting of:



;



;



;


;


;


;


;


;


;


F
HN
N
H_3C
N
O
O
OH
;


OEt
N
F
N
O
O
OH
;


F
F
OEt
N
N
O
O
OH
;


Cl
OEt
N
N
O
O
OH
;


F
Cl
OEt
N
N
O
O
OH
;


Cl
Cl
OEt
N
N
O
O
OH
;



;



;



;

and pharmaceutically acceptable salts thereof.

18. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

19. A method of inhibiting HIV integrase in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of the compound according to claim 1, or a pharmaceutically acceptable salt thereof.

20. A method for preventing or treating infection by HIV or for preventing, treating or delaying the onset of AIDS in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of the compound according to claim 1, or a pharmaceutically acceptable salt thereof.

21. A pharmaceutical composition which comprises the product prepared by combining an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

22. A combination useful for inhibiting HIV integrase, for treating or preventing infection by HIV, or for preventing, treating or delaying the onset of AIDS, which is a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of an HIV infection/AIDS antiviral agent selected from the group consisting of HIV protease inhibitors, non-nucleoside HIV reverse transcriptase inhibitors and nucleoside HIV reverse transcriptase inhibitors.